Insider Selling: Tempus AI (NASDAQ:TEM) COO Sells $321,300.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) COO Ryan Fukushima sold 5,000 shares of Tempus AI stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $64.26, for a total value of $321,300.00. Following the sale, the chief operating officer owned 148,808 shares in the company, valued at $9,562,402.08. This represents a 3.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Ryan Fukushima also recently made the following trade(s):

• On Monday, December 1st, Ryan Fukushima sold 5,000 shares of Tempus AI stock. The stock was sold at an average price of $75.72, for a total transaction of $378,600.00.
• On Tuesday, November 18th, Ryan Fukushima sold 10,099 shares of Tempus AI stock. The shares were sold at an average price of $65.54, for a total transaction of $661,888.46.
• On Monday, November 3rd, Ryan Fukushima sold 5,000 shares of Tempus AI stock. The shares were sold at an average price of $89.03, for a total transaction of $445,150.00.

Tempus AI Price Performance

Shares of TEM stock opened at $66.27 on Friday. The firm has a fifty day moving average of $70.25 and a two-hundred day moving average of $73.32. The firm has a market cap of $11.79 billion, a P/E ratio of -55.69 and a beta of 5.22. Tempus AI, Inc. has a 1-year low of $31.36 and a 1-year high of $104.32. The company has a debt-to-equity ratio of 2.45, a current ratio of 3.28 and a quick ratio of 3.12.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.05. The business had revenue of $334.21 million for the quarter, compared to analysts’ expectations of $328.89 million. Tempus AI had a negative net margin of 18.45% and a negative return on equity of 73.21%. The company’s quarterly revenue was up 84.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.46) earnings per share. As a group, research analysts anticipate that Tempus AI, Inc. will post -6.15 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tempus AI

Institutional investors have recently modified their holdings of the company. MetLife Investment Management LLC bought a new stake in Tempus AI in the 1st quarter valued at about $225,000. Royal Bank of Canada raised its holdings in shares of Tempus AI by 201.2% during the first quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock valued at $1,253,000 after buying an additional 17,359 shares during the last quarter. Advisors Asset Management Inc. boosted its position in shares of Tempus AI by 753.9% during the first quarter. Advisors Asset Management Inc. now owns 17,377 shares of the company’s stock worth $838,000 after buying an additional 15,342 shares during the period. NewEdge Advisors LLC grew its holdings in Tempus AI by 2,420.6% in the 1st quarter. NewEdge Advisors LLC now owns 36,548 shares of the company’s stock worth $1,763,000 after buying an additional 35,098 shares in the last quarter. Finally, Arete Wealth Advisors LLC acquired a new stake in Tempus AI in the 1st quarter valued at approximately $314,000. Institutional investors own 24.22% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on TEM. TD Cowen lowered Tempus AI from a “buy” rating to a “hold” rating and set a $88.00 price target on the stock. in a research report on Tuesday, October 21st. Morgan Stanley boosted their target price on shares of Tempus AI from $80.00 to $85.00 and gave the company an “overweight” rating in a research note on Monday, December 1st. JPMorgan Chase & Co. reduced their price target on shares of Tempus AI from $85.00 to $80.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. HC Wainwright decreased their price target on shares of Tempus AI from $98.00 to $89.00 and set a “buy” rating for the company in a report on Friday, November 7th. Finally, Canaccord Genuity Group dropped their price objective on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, December 22nd. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $84.00.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.